IL-7Rα signaling potentiates the anti-tumor activity of NK92 cells

Read full text Summarise with VIRAT
Authors: Chunli Wang, Seokmin Kim, Ling-Zu Kong, In-Hwan Jang, Seona Jo, Sunyoung Lee, Soo Yun Lee, Kee Kwang Kim, Tae‐Don Kim
Cited by: 0
References: 53

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background Natural killer (NK) cells are promising candidates for cancer immunotherapy due to their safety and potent anti-tumor activity. However, their therapeutic efficacy is often limited by poor persistence and activity within the tumor microenvironment (TME) caused by a lack of essential cytokines. Methods To overcome cytokine dependence, we engineered NK92, primary NK (pNK), and chimeric antigen receptor (CAR)-NK92 cells to express an interleukin-7 receptor with an insertion mutation (IL-7R-IM), which induces constitutive signaling. We evaluated the proliferation, viability, and cytotoxicity of these cells in vitro and analyzed downstream signaling pathways using RNA sequencing and western blotting. The in vivo anti-tumor efficacy was assessed using a metastatic leukemia xenograft mouse model. Results NK92-IL-7R-IM cells exhibited sustained proliferation and high viability independent of exogenous cytokines, superior to IL-2-activated NK cells. This enhanced functionality was driven by the constitutive activation of the JAK/STAT, AKT, and ERK signaling pathways, leading to the upregulation of cytotoxicity-related genes ( GZMA , GZMB ) and anti-apoptotic genes ( BCL2L1 ). In vivo , NK92-IL-7R-IM cells demonstrated significantly potent anti-tumor activity and extended survival compared to control groups. Furthermore, the IL-7R-IM strategy successfully enhanced the function of CAR-NK cells targeting EphA2, EGFR, and CD5 antigens. Conclusions The expression of IL-7R-IM confers cytokine independence and robust anti-tumor activity to NK and CAR-NK cells. This strategy offers a practical solution to improve the persistence and efficacy of off-the-shelf NK cell therapeutics for clinical application.

Fields of Study & Subjects

Immune Cell Function and Interaction CAR-T cell therapy research Immunotherapy and Immune Responses

Publication details

Journal / source
Frontiers in Immunology
Volume
17
Pages
1768539–1768539
Publication date
30 March 2026
Language
EN